OBJECTIVES AND METHODS: The interaction between the two best documented risk factors (human leukocyte antigen [HLA] class II [DRB1*1501 positivity] and Epstein-Barr virus [elevated Epstein-Barr nuclear antigen 1 (EBNA-1) antibody reactivity]) for multiple sclerosis (MS) was studied in a case-control study of biobank samples from 109 MS cases and 212 matched referents. RESULTS: Multivariate logistic regression analysis showed that both were statistically significant in both sexes. HLA DRB1*1501-positive referents had higher EBNA-1 reactivity than HLA-negative referents. Less EBNA-1 reactivity was required to increase the MS risk in HLA DRB1*1501-positives than in HLA-negatives. CONCLUSION: We suggest that HLA DRB1*1501-positive individuals have an increased vulnerability to EBV-induced autoimmunity.
OBJECTIVES AND METHODS: The interaction between the two best documented risk factors (human leukocyte antigen [HLA] class II [DRB1*1501 positivity] and Epstein-Barr virus [elevated Epstein-Barr nuclear antigen 1 (EBNA-1) antibody reactivity]) for multiple sclerosis (MS) was studied in a case-control study of biobank samples from 109 MS cases and 212 matched referents. RESULTS: Multivariate logistic regression analysis showed that both were statistically significant in both sexes. HLA DRB1*1501-positive referents had higher EBNA-1 reactivity than HLA-negative referents. Less EBNA-1 reactivity was required to increase the MS risk in HLA DRB1*1501-positives than in HLA-negatives. CONCLUSION: We suggest that HLA DRB1*1501-positive individuals have an increased vulnerability to EBV-induced autoimmunity.
Authors: Frederick W Miller; Lars Alfredsson; Karen H Costenbader; Diane L Kamen; Lorene M Nelson; Jill M Norris; Anneclaire J De Roos Journal: J Autoimmun Date: 2012-06-25 Impact factor: 7.094
Authors: Philip L De Jager; Lori B Chibnik; Jing Cui; Joachim Reischl; Stephan Lehr; K Claire Simon; Cristin Aubin; David Bauer; Jürgen F Heubach; Rupert Sandbrink; Michaela Tyblova; Petra Lelkova; Eva Havrdova; Christoph Pohl; Dana Horakova; Alberto Ascherio; David A Hafler; Elizabeth W Karlson Journal: Lancet Neurol Date: 2009-10-29 Impact factor: 44.182
Authors: K C Simon; I A F van der Mei; K L Munger; A Ponsonby; J Dickinson; T Dwyer; P Sundström; A Ascherio Journal: Neurology Date: 2010-04-07 Impact factor: 9.910
Authors: D Csuka; D Simon; R Hóbor; K Uray; Z Prohászka; Z Bánlaki; P K Jani; Á Szilágyi; F Hudecz; K Rajczy; G Beke; A Boros Major; A Tordai; Z Illés; T Berki; L Czirják; G Füst Journal: Clin Exp Immunol Date: 2013-03 Impact factor: 4.330
Authors: Rohina Rubicz; Robert Yolken; Eugene Drigalenko; Melanie A Carless; Thomas D Dyer; Lara Bauman; Phillip E Melton; Jack W Kent; John B Harley; Joanne E Curran; Matthew P Johnson; Shelley A Cole; Laura Almasy; Eric K Moses; Nikhil V Dhurandhar; Ellen Kraig; John Blangero; Charles T Leach; Harald H H Göring Journal: PLoS Genet Date: 2013-01-10 Impact factor: 5.917